EPAC 5376753

EPAC 5376753 is an allosterically inhibitor of Epac which inhibits Epac1 with an IC50 of 4 µM in Swiss 3T3 cells.

Signaling Pathways >> Others >> Others

Research Areas >> Cancer

Research Areas >> Cardiovascular Disease

Research Areas >> Metabolic Disease

IC50: 4 µM (Epac)[1]

Epac is a key mediator of cAMP signaling. EPAC 5376753, the thiobarbituric acid modification of 5225554, has a greater ability to decrease the conformational changes of Epac necessary for its activation and to inhibit Epac signaling in cells. 5376753 selectively inhibits Epac-mediated migration in fibroblasts[1].

Swiss 3T3 cells are treated with EPAC 5376753 (1, 10, 25, 50, 75, 100 μM) or 1% dimethyl sulfoxide for 48 h. Cell viability is assessed using the CellTiter-Glo assay[1].

[1]. Brown LM, et al. Allosteric inhibition of Epac: computational modeling and experimental validation to identify allosteric sites and inhibitors. J Biol Chem. 2014 Oct 17;289(42):29148-57.

Captisol | Cyclosporin A | H2DCFDA | 0MPTP hydrochloride | GW4869 | Etomoxir | TD139 | Mitoquinone mesylate | GSK2795039 | JC-1 | BAPTA-AM | AP 20187 | Setanaxib (GKT137831) | D-Luciferin | Crotaline